oxaliplatin (SR96669) + capecitabine + sorafenib
Phase 3Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatic Neoplasm Malignant
Conditions
Hepatic Neoplasm Malignant
Trial Timeline
Jul 1, 2011 → Aug 1, 2015
NCT ID
NCT01245582About oxaliplatin (SR96669) + capecitabine + sorafenib
oxaliplatin (SR96669) + capecitabine + sorafenib is a phase 3 stage product being developed by Sanofi for Hepatic Neoplasm Malignant. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01245582. Target conditions include Hepatic Neoplasm Malignant.
What happened to similar drugs?
3 of 17 similar drugs in Hepatic Neoplasm Malignant were approved
Approved (3) Terminated (4) Active (12)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01245582 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Hepatic Neoplasm Malignant
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ITF2357 | Biotrial | Phase 1 | 19 |
| GB1211 + Placebo | Comac Medical | Phase 1/2 | 18 |
| ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results) | Idorsia | Phase 1 | 23 |
| Olomorasib | Eli Lilly | Phase 1 | 29 |
| Simufilam | Cassava Sciences | Phase 1 | 19 |
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 40 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 35 |
| DS-3201b | Daiichi Sankyo | Phase 1 | 29 |
| Quizartinib | Daiichi Sankyo | Phase 1 | 29 |
| Quizartinib | Daiichi Sankyo | Phase 1 | 36 |
| Pexidartinib | Daiichi Sankyo | Phase 1 | 29 |
| Tivantinib + Tivantinib + Tivantinib + Tivantinib | Daiichi Sankyo | Phase 1 | 29 |
| Bocidelpar | Astellas Pharma | Phase 1 | 29 |
| fezolinetant | Astellas Pharma | Phase 1 | 29 |
| enzalutamide | Astellas Pharma | Phase 1 | 29 |
| ASP015K | Astellas Pharma | Phase 1 | 29 |
| ASP2215 | Astellas Pharma | Phase 1 | 29 |
| BPN14770 | Shionogi | Phase 1 | 29 |
| S-217622 | Shionogi | Phase 1 | 29 |
| Lemborexant | Eisai | Phase 1 | 29 |